Charles Cliff Duncan
CIK: 0002130896
Associated companies
Transaction History
| VNDA | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 | View on chart |
| VNDA | ▲ Buy | Grant | 57,101 | $0 | 4/22/2026 | View on chart |
| VNDA | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 | View on chart |
| VNDA | ▲ Buy | Grant | 57,101 | $0 | 4/22/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Oppenheimer Launches Coverage on Vanda Pharmaceuticals
Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.
Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.